These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2594910)

  • 1. Infusions of cholecystokinin octapeptide into the ventral tegmental area potentiate amphetamine conditioned place preferences.
    Pettit HO; Mueller K
    Psychopharmacology (Berl); 1989; 99(3):423-6. PubMed ID: 2594910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amphetamine regulation of mesolimbic dopamine/cholecystokinin neurotransmission.
    Hurd YL; Lindefors N; Brodin E; Brené S; Persson H; Ungerstedt U; Hökfelt T
    Brain Res; 1992 Apr; 578(1-2):317-26. PubMed ID: 1354999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opposite actions of CCK-8 on amphetamine-induced hyperlocomotion and stereotypy following intracerebroventricular and intra-accumbens injections in rats.
    Weiss F; Tanzer DJ; Ettenberg A
    Pharmacol Biochem Behav; 1988 Jun; 30(2):309-17. PubMed ID: 3174761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microinjection of cholecystokinin into the rat ventral tegmental area potentiates dopamine-induced hypolocomotion.
    Crawley JN
    Synapse; 1989; 3(4):346-55. PubMed ID: 2740993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of cholecystokinin on central monoaminergic pathways.
    Widerlöv E; Kalivas PW; Lewis MH; Prange AJ; Breese GR
    Regul Pept; 1983 May; 6(2):99-109. PubMed ID: 6308717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased neuronal responsiveness to cholecystokinin and dopamine induced by lesioning mesolimbic dopaminergic neurons: an electrophysiological study in the rat.
    Debonnel G; de Montigny C
    Synapse; 1988; 2(5):537-45. PubMed ID: 2903570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholecystokinin potentiates dopamine inhibition of mesencephalic dopamine neurons in vitro.
    Brodie MS; Dunwiddie TV
    Brain Res; 1987 Nov; 425(1):106-13. PubMed ID: 3427413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine and conditioned reinforcement. II. Contrasting effects of amphetamine microinjection into the nucleus accumbens with peptide microinjection into the ventral tegmental area.
    Kelley AE; Delfs JM
    Psychopharmacology (Berl); 1991; 103(2):197-203. PubMed ID: 1709289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracellular dopamine in the anterior nucleus accumbens is distinctly affected by ventral tegmental area administration of cholecystokinin and apomorphine: data from in vivo voltammetry.
    Reum T; Fink H; Marsden CA; Morgenstern R
    Neuropeptides; 1998 Apr; 32(2):161-6. PubMed ID: 9639255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesoaccumbens dopamine-opiate interactions in the control over behaviour by a conditioned reinforcer.
    Phillips GD; Robbins TW; Everitt BJ
    Psychopharmacology (Berl); 1994 Mar; 114(2):345-59. PubMed ID: 7838928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional effects of apomorphine on rat brain cholecystokinin-8 like immunoreactivity following electrolytic lesions of the ventral tegmental area.
    Fukamauchi F; Takahashi R
    Neuropeptides; 1988; 11(2):63-7. PubMed ID: 3368037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microinjections of nanogram amounts of sulfated cholecystokinin octapeptide into the rat nucleus accumbens attenuates brain stimulation reward.
    Vaccarino FJ; Koob GF
    Neurosci Lett; 1984 Nov; 52(1-2):61-6. PubMed ID: 6098878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of administration of cholecystokinin into the VTA on DA overflow in nucleus accumbens and amygdala of freely moving rats.
    Hamilton ME; Freeman AS
    Brain Res; 1995 Aug; 688(1-2):134-42. PubMed ID: 8542299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triazolam attenuates amphetamine but not morphine conditioned place preferences.
    Pettit HO; Batsell WR; Mueller K
    Psychopharmacology (Berl); 1989; 98(4):483-6. PubMed ID: 2505288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amphetamine injected into the ventral tegmental area sensitizes the nucleus accumbens dopaminergic response to systemic amphetamine: an in vivo microdialysis study in the rat.
    Vezina P
    Brain Res; 1993 Mar; 605(2):332-7. PubMed ID: 8386970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCK-8 modulation of mesolimbic dopamine: antagonism of amphetamine-stimulated behaviors.
    Schneider LH; Alpert JE; Iversen SD
    Peptides; 1983; 4(5):749-53. PubMed ID: 6318205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral evidence for cholecystokinin modulation of dopamine in the mesolimbic pathway.
    Crawley JH
    Prog Clin Biol Res; 1985; 192():131-8. PubMed ID: 4080706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleus accumbens cholecystokinin (CCK) can either attenuate or potentiate amphetamine-induced locomotor activity: evidence for rostral-caudal differences in accumbens CCK function.
    Vaccarino FJ; Rankin J
    Behav Neurosci; 1989 Aug; 103(4):831-6. PubMed ID: 2765186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conditioned place preference from ventral tegmental injection of morphine in neonatal rats.
    Barr GA; Rossi G
    Brain Res Dev Brain Res; 1992 Mar; 66(1):133-6. PubMed ID: 1600627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopaminergic substrates of amphetamine-induced place preference conditioning.
    Spyraki C; Fibiger HC; Phillips AG
    Brain Res; 1982 Dec; 253(1-2):185-93. PubMed ID: 6817850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.